Biomarker-Driven Insights into Immune Checkpoint Inhibitor Therapy in Small-Cell Lung Cancer.
Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options, and the integration of immune checkpoint inhibitors (ICIs) into treatment regimens has reshaped the therapeutic landscape. However, challenges such as rapid resistance and lack of effective predictive biomarkers remain. This revie...